Details for Patent: 6,770,675
Summary for Patent: 6,770,675
| Title: | Compositions and methods for reducing ocular hypertension | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Kenneth Warren Reed, Shau Fong Yen, Mary Sou, Regina Flinn Peacock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | R Tech Ueno Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US09/812,162 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 6,770,675: Claim Scope, Expiration, Litigation Risk, and Ophthalmic Formulation LandscapeU.S. Patent No. 6,770,675 covers ophthalmic compositions that combine a docosanoid active agent with two nonionic surfactants at a combined concentration below the amount required for either surfactant alone to solubilize the active agent. It also covers a separate preservative-stabilization method using a docosanoid, polysorbate 80, benzalkonium chloride, mannitol, and optionally EDTA. The patent is directed primarily to formulation technology rather than the docosanoid molecule itself. Its practical value was strongest for ophthalmic products containing isopropyl unoprostone, particularly formulations designed to balance solubility, ocular tolerability, and preservative effectiveness. The patent’s U.S. term has expired under the ordinary 20-year patent-term framework, so it does not create a current U.S. blocking right. Its claims remain relevant for historical freedom-to-operate analysis, patent-family mapping, and evaluation of later continuation or foreign rights. What does U.S. Patent 6,770,675 cover?The patent contains two distinct claim groups:
The claims use “comprising,” which is an open-ended transitional term. A formulation containing the claimed components may still fall within the claims if it includes additional excipients, buffers, tonicity agents, chelators, viscosity modifiers, or preservatives. What is the scope of independent claim 1?Claim 1 requires four principal elements:
The critical limitation is comparative and functional. The total concentration of both surfactants must be lower than the surfactant concentration that would be required to solubilize the docosanoid when either surfactant is evaluated individually. This limitation distinguishes the claimed formulation from a conventional micellar formulation in which one surfactant is used at a concentration sufficient by itself to solubilize the active agent. The claim instead targets a synergistic or cooperative surfactant system that improves formulation performance at a lower combined surfactant load. How the claim’s solubility limitation would be analyzedA likely infringement or validity analysis would require comparison of:
The claim does not define “solubilize.” That creates an evidentiary issue. Solubility could be assessed by visual clarity, filtered assay, equilibrium solubility, particle-count testing, or another validated analytical method. The relevant comparison must use consistent conditions for the individual-surfactant controls and the dual-surfactant formulation. A formulation can satisfy the claim even if the two surfactants together provide substantial solubilization. The claim does not require poor solubility. It requires that the combined amount be below the amount needed for either surfactant alone. What formulations are protected by claims 2 through 5?Claims 2 through 5 progressively narrow claim 1.
Claim 5 is not a stand-alone claim. It incorporates all limitations of claims 1 through 4 and adds the 0.3% to 2.0% total surfactant range. A formulation outside that range may still infringe claim 4 or claim 1 if the other limitations are met. The use of “about” gives the concentration limitation some numerical flexibility. The applicable range would depend on prosecution history, specification disclosure, experimental examples, and the extent to which a proposed concentration performs the same claimed function. What are the likely covered surfactant combinations?The claim language points to combinations such as:
The claims do not require a particular ratio between the two surfactants. A product with a very small amount of one surfactant and a substantially larger amount of the other could remain within the literal scope if the total concentration and comparative solubility requirement are satisfied. How broad is the docosanoid limitation?“Docosanoid” is broader than isopropyl unoprostone. It generally refers to biologically active compounds derived from or structurally related to 22-carbon fatty-acid pathways. The specification and prosecution record would determine the operative construction, but claim 1 is not expressly limited to one active ingredient. Claim 8 is narrower. It specifically identifies:
This distinction matters commercially. A product using isopropyl unoprostone could be evaluated under both the broad composition claims and the narrower preservative-method claim. A different docosanoid could potentially fall within claims 1 and 6 while avoiding claim 8. What does claim 6 protect?Claim 6 covers a method of reducing ocular hypertension by administering to ocular fluids or ocular tissue a composition having the same core features as claim 1. The claim requires:
The method claim does not specify:
Because the claim is open-ended and does not prescribe a particular dosage regimen, a broad range of topical ophthalmic administration protocols could potentially satisfy its structural limitations. The principal disputes would likely concern whether the administered product contains two qualifying surfactants and whether the comparative solubility limitation is met. What does claim 7 protect?Claim 7 is materially different from claims 1 through 6. It covers a method for increasing the effectiveness of a strong preservative in a solution containing a docosanoid active agent and a nonionic surfactant. The method requires admixing:
Unlike claim 1, claim 7 does not require two nonionic surfactants. It focuses on the interaction among:
Claim 7 therefore addresses a different formulation problem. A company could avoid claims 1 through 6 by using only one surfactant, yet still face claim 7 if its formulation uses the claimed preservative-restoration strategy. What do claims 8 and 9 add?Claim 8 specifies the principal formulation combination:
Claim 9 adds EDTA to the method of claim 7. EDTA, commonly used as a chelating agent, can affect preservative performance by binding metal ions and altering microbial susceptibility or preservative interactions. Claim 9 is narrower than claim 7 but may be easier to test analytically because the component list is more specific. When did U.S. Patent 6,770,675 lose exclusivity?U.S. Patent 6,770,675 issued on August 3, 2004. Its enforceable U.S. term expired under the standard 20-year term calculated from the relevant nonprovisional filing date. The patent is therefore expired and does not present a current U.S. patent-enforcement barrier.
Patent-term adjustment, patent-term extension, terminal disclaimers, and priority-chain details can affect the exact expiration date. Those mechanisms do not change the present conclusion that the patent is no longer enforceable in the United States. The expiration of this patent does not establish that all related patents have expired. Continuations, divisionals, foreign counterparts, or separate active-ingredient patents must be assessed independently. What is the Orange Book status of the patent?The patent is not a current source of Orange Book exclusivity. Orange Book relevance depends on whether the patent was listed against an approved drug product and whether the listing remained active during the product’s commercial life. For an isopropyl-unoprostone product, the relevant regulatory history includes Rescula, an ophthalmic product associated with isopropyl unoprostone. FDA approval history, product discontinuation status, and Orange Book listing history must be separated:
The FDA Orange Book should be reviewed for historical patent-listing data, while FDA Drugs@FDA should be used for approval and marketing-status records.[2,3] Were Paragraph IV challenges likely under this patent?A Paragraph IV certification would be relevant only if the patent was listed in the Orange Book against the reference listed drug and remained unexpired when an ANDA was submitted. For a formulation patent of this type, an ANDA applicant could potentially argue that:
No current Paragraph IV risk arises from an expired patent. Historical ANDA litigation would require a docket-specific review of the relevant product, patent listing, and filing date. The patent number alone does not establish that a Paragraph IV certification or 30-month stay occurred. What patent litigation affects U.S. Patent 6,770,675?The patent’s present litigation risk is zero because an expired U.S. patent cannot support a new infringement action for post-expiration conduct. Historical litigation risk is a separate question. A complete litigation review should distinguish:
The supplied claims do not identify a litigation history, settlement agreement, or license. The patent itself does not establish that any settlement or license existed. How strong was the patent estate?The patent was technically focused and commercially strongest against a formulation that used the specified excipient architecture. Its strengths and weaknesses can be summarized as follows:
The functional solubility limitation can make claim 1 difficult to invalidate for lack of written description if the specification provides representative examples across the claimed genus. It can also make infringement more fact-intensive because the parties must agree on test conditions and analytical endpoints. At the same time, functional language can create enablement, indefiniteness, and proof-of-infringement issues. The scope is less predictable than a claim limited to fixed percentages and named excipients. What generic launch scenarios existed?For a generic or alternative ophthalmic product, the principal launch routes would have included: Formulation design-aroundA competitor could use:
Paragraph IV certificationIf the patent was listed and unexpired at the time of ANDA filing, an applicant could certify that the patent was invalid, unenforceable, or not infringed. Claim 1’s comparative solubility requirement would have been a central noninfringement issue. Paragraph III certificationAfter patent expiration, an applicant could certify that it would not market until the listed patent expired. That barrier no longer applies to this patent. 505(b)(2) pathwayA product with a different formulation, delivery system, or clinical-use profile could potentially use the 505(b)(2) pathway, subject to FDA requirements and any remaining listed patents or exclusivities associated with the reference product. How does this patent compare with molecule, method-of-use, and manufacturing patents?
The patent does not cover manufacture of isopropyl unoprostone, filling operations, container systems, or generic ophthalmic products that do not practice the claimed formulation or method. What geographic coverage exists?U.S. Patent 6,770,675 provides protection only in the United States. Foreign equivalents must be evaluated separately by jurisdiction. Relevant geographic questions include:
U.S. expiration does not terminate foreign rights. Conversely, foreign patent rights do not create U.S. infringement exposure. What manufacturing and intellectual-property barriers remain?The patent does not create a current U.S. manufacturing barrier. Remaining barriers may include:
For a generic developer, the most important technical work would be confirming that the selected surfactant system does not trigger claim 1 or claim 6 in jurisdictions where a corresponding patent remains active, and that the preservative system does not reproduce the claim 7 architecture. Key Takeaways
FAQsDoes U.S. Patent 6,770,675 cover all ophthalmic formulations containing unoprostone?No. It covers formulations that satisfy the specific docosanoid, nonionic-surfactant, carrier, and comparative solubility limitations. Claim 8 is narrower and requires isopropyl unoprostone, benzalkonium chloride, polysorbate 80, mannitol, and the required ophthalmic formulation context. Can a formulation avoid the patent by using polysorbate 80 alone?A formulation using only polysorbate 80 would generally not meet the two-surfactant requirement of claims 1 through 6. It could still require analysis under claim 7 if it uses a docosanoid, strong preservative, mannitol, and the claimed preservative-effectiveness mechanism. Does claim 5 cover every formulation containing 0.3% to 2.0% surfactant?No. Claim 5 incorporates all limitations of claims 1 through 4. The formulation must also contain the claimed docosanoid, polysorbate/Brij-type surfactants, ophthalmically acceptable carrier, and comparative solubility relationship. Is mannitol required in the dual-surfactant composition claims?No. Mannitol is required by claim 7 and its dependent claims. Claims 1 through 6 do not expressly require mannitol. Does patent expiration eliminate FDA approval requirements for a generic ophthalmic product?No. Patent expiration removes the patent barrier but does not eliminate FDA requirements for an ANDA, 505(b)(2) application, sterility, quality, bioequivalence, manufacturing controls, or labeling. References
More… ↓ |
Drugs Protected by US Patent 6,770,675
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
